Abstract
Peptide receptor radionuclide therapy (PRRT) consists in the systemic administration of a synthetic peptide, labelled with a suitable beta-emitting radionuclide, able to irradiate tumours and their metastases via the internalization through a specific receptor, overexpressed on the cell membrane. After 15 years of experience, we can state that PRRT with 90Y- labelled peptides is generally well tolerated. Acute side effects are usually mild, some of which are related to the co-administration of amino acids, such as nausea. Others are related to the radiopeptide, such as fatigue or the exacerbation of an endocrine syndrome, which rarely occurs in functioning tumours. Chronic and permanent effects on target organs, particularly the kidneys and the bone marrow, are generally mild if the necessary precautions are taken. Currently, the potential risk to kidney and red marrow limits the amount of radioactivity that may be administered. However, when tumour masses are irradiated with adequate doses, volume reduction may be observed. 90Y-octreotide has been the most widely used radiopeptide in the first 8-10 years of experience. Unfortunately, all of the published results derive from different and inhomogeneous phase I/II studies. Hence, a direct comparison is virtually impossible to date. Nevertheless, even with these limitations, objective responses are registered in 10-34% of patients. The optimal timing of 90Y-DOTATOC in the management of somatostatin receptor (SSTR)-positive tumours and the way in which it should be integrated with other treatments have yet to be defined, and prospective phase II/III trials comparing the efficacy and toxicity of different schemes of 90Y-DOTATOC administration are still warranted.
| Original language | English |
|---|---|
| Journal | European Journal of Nuclear Medicine and Molecular Imaging |
| Volume | 39 |
| Issue number | SUPPL.1 |
| DOIs | |
| Publication status | Published - Feb 2012 |
Fingerprint
Keywords
- Y-DOTATOC
- Neuroendocrine tumours
- Peptide receptor radionuclide therapy
- PRRT
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
Cite this
Yttrium-labelled peptides for therapy of NET. / Bodei, Lisa; Cremonesi, Marta; Grana, Chiara M.; Chinol, Marco; Baio, Silvia M.; Severi, Stefano; Paganelli, Giovanni.
In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 39, No. SUPPL.1, 02.2012.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Yttrium-labelled peptides for therapy of NET
AU - Bodei, Lisa
AU - Cremonesi, Marta
AU - Grana, Chiara M.
AU - Chinol, Marco
AU - Baio, Silvia M.
AU - Severi, Stefano
AU - Paganelli, Giovanni
PY - 2012/2
Y1 - 2012/2
N2 - Peptide receptor radionuclide therapy (PRRT) consists in the systemic administration of a synthetic peptide, labelled with a suitable beta-emitting radionuclide, able to irradiate tumours and their metastases via the internalization through a specific receptor, overexpressed on the cell membrane. After 15 years of experience, we can state that PRRT with 90Y- labelled peptides is generally well tolerated. Acute side effects are usually mild, some of which are related to the co-administration of amino acids, such as nausea. Others are related to the radiopeptide, such as fatigue or the exacerbation of an endocrine syndrome, which rarely occurs in functioning tumours. Chronic and permanent effects on target organs, particularly the kidneys and the bone marrow, are generally mild if the necessary precautions are taken. Currently, the potential risk to kidney and red marrow limits the amount of radioactivity that may be administered. However, when tumour masses are irradiated with adequate doses, volume reduction may be observed. 90Y-octreotide has been the most widely used radiopeptide in the first 8-10 years of experience. Unfortunately, all of the published results derive from different and inhomogeneous phase I/II studies. Hence, a direct comparison is virtually impossible to date. Nevertheless, even with these limitations, objective responses are registered in 10-34% of patients. The optimal timing of 90Y-DOTATOC in the management of somatostatin receptor (SSTR)-positive tumours and the way in which it should be integrated with other treatments have yet to be defined, and prospective phase II/III trials comparing the efficacy and toxicity of different schemes of 90Y-DOTATOC administration are still warranted.
AB - Peptide receptor radionuclide therapy (PRRT) consists in the systemic administration of a synthetic peptide, labelled with a suitable beta-emitting radionuclide, able to irradiate tumours and their metastases via the internalization through a specific receptor, overexpressed on the cell membrane. After 15 years of experience, we can state that PRRT with 90Y- labelled peptides is generally well tolerated. Acute side effects are usually mild, some of which are related to the co-administration of amino acids, such as nausea. Others are related to the radiopeptide, such as fatigue or the exacerbation of an endocrine syndrome, which rarely occurs in functioning tumours. Chronic and permanent effects on target organs, particularly the kidneys and the bone marrow, are generally mild if the necessary precautions are taken. Currently, the potential risk to kidney and red marrow limits the amount of radioactivity that may be administered. However, when tumour masses are irradiated with adequate doses, volume reduction may be observed. 90Y-octreotide has been the most widely used radiopeptide in the first 8-10 years of experience. Unfortunately, all of the published results derive from different and inhomogeneous phase I/II studies. Hence, a direct comparison is virtually impossible to date. Nevertheless, even with these limitations, objective responses are registered in 10-34% of patients. The optimal timing of 90Y-DOTATOC in the management of somatostatin receptor (SSTR)-positive tumours and the way in which it should be integrated with other treatments have yet to be defined, and prospective phase II/III trials comparing the efficacy and toxicity of different schemes of 90Y-DOTATOC administration are still warranted.
KW - Y-DOTATOC
KW - Neuroendocrine tumours
KW - Peptide receptor radionuclide therapy
KW - PRRT
UR - http://www.scopus.com/inward/record.url?scp=84863797969&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863797969&partnerID=8YFLogxK
U2 - 10.1007/s00259-011-2002-y
DO - 10.1007/s00259-011-2002-y
M3 - Article
C2 - 22388625
AN - SCOPUS:84863797969
VL - 39
JO - European Journal of Pediatrics
JF - European Journal of Pediatrics
SN - 0340-6199
IS - SUPPL.1
ER -